Press release
Diabetic Kidney Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Janssen Pharma, Astrazeneca, Aurobindo Pharma, Teva Pharma, Sanofi, Novartis, Sun Pharma, Bayer
"Diabetic Kidney Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.
The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report: https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years.
• Diabetic Kidney Disease companies working in the treatment market are Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others, are developing therapies for the Diabetic Kidney Disease treatment
• Emerging Diabetic Kidney Disease therapies in the different phases of clinical trials are- ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others are expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.
• In July 2021, In people with chronic kidney disease linked with type 2 diabetes, the FDA approved Bayer Ag's Kerendia (finerenone) tablets to lower the risk of declining kidney function, kidney failure, non-fatal heart attacks, cardiovascular death, and hospitalization due to heart failure.
Diabetic Kidney Disease Overview
Diabetic nephropathy, another name for diabetic kidney disease (DKD), is a progressive, long-term condition that worsens with time. About 30% of patients with type 1 diabetes (T1D) and 40% of those with type 2 diabetes (T2D) have diabetic nephropathy, a serious long-term consequence.
Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• ORBCEL-M: Orbsen Therapeutics
• DMX-200: Dimerix Bioscience
• INV-202: Inversago Pharma
• CSL346: CSL Behring
• Bardoxolone methyl: Kyowa kirin
Diabetic Kidney Disease Pipeline Therapeutics Assessment
• Diabetic Kidney Disease Assessment by Product Type
• Diabetic Kidney Disease By Stage and Product Type
• Diabetic Kidney Disease Assessment by Route of Administration
• Diabetic Kidney Disease By Stage and Route of Administration
• Diabetic Kidney Disease Assessment by Molecule Type
• Diabetic Kidney Disease by Stage and Molecule Type
DelveInsight's Diabetic Kidney Disease Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies at:
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Diabetic Kidney Disease are - Janssen Pharma, Astrazeneca, Aurobindo Pharma, Teva Pharma, Sanofi, Novartis, Sun Pharma, Bayer, Par Pharma, and others.
Diabetic Kidney Disease Pipeline Analysis:
The Diabetic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.
• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diabetic Kidney Disease Pipeline Market Drivers
• Increasing prevalence of diabetes worldwide, rising geriatric population, increasing demand of novel therapies are some of the important factors that are fueling the Diabetic Kidney Disease Market.
Diabetic Kidney Disease Pipeline Market Barriers
• However, lack of skilled professionals to treat diabetic kidney disease in less developed countries, stringent regulatory guidelines and other factors are creating obstacles in the Diabetic Kidney Disease Market growth.
Scope of Diabetic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others
• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers
Request for Sample PDF Report for Diabetic Kidney Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Diabetic Kidney Disease Report Introduction
2. Diabetic Kidney Disease Executive Summary
3. Diabetic Kidney Disease Overview
4. Diabetic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Kidney Disease Pipeline Therapeutics
6. Diabetic Kidney Disease Late Stage Products (Phase II/III)
7. Diabetic Kidney Disease Mid Stage Products (Phase II)
8. Diabetic Kidney Disease Early Stage Products (Phase I)
9. Diabetic Kidney Disease Preclinical Stage Products
10. Diabetic Kidney Disease Therapeutics Assessment
11. Diabetic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Kidney Disease Key Companies
14. Diabetic Kidney Disease Key Products
15. Diabetic Kidney Disease Unmet Needs
16 . Diabetic Kidney Disease Market Drivers and Barriers
17. Diabetic Kidney Disease Future Perspectives and Conclusion
18. Diabetic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Diabetic Kidney Disease Market https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Diabetic Kidney Disease Epidemiology https://www.delveinsight.com/report-store/diabetic-kidney-disease-dkd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Oncology Drugs Market
https://www.delveinsight.com/report-store/oncology-drugs-market
Oncology Drugs Market By Therapy Type (Chemotherapy, Hormonal Therapy, Targeted Therapy [Gene Therapy And Immunotherapy], And Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancers, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is estimated to grow at a healthy CAGR forecast till 2028 due to rising prevalence of various cancers such as lung and breast cancers and growing demand for targeted therapies for cancer treatment.
Biologics Market
https://www.delveinsight.com/report-store/biologics-market
Biologics Market By Product Type (Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Protiens, And Others), By Application (Oncology, Immunology, Infectious Diseases, Neurological Diseases, And Others), By Manufacturing Type (In-House And Outsourced), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to rising prevalence of autoimmune disorders such as rheumatoid arthiritis and genetic disorders.
Biosimilar Market
https://www.delveinsight.com/report-store/biosimilars-market
Biosimilars Market By Product Class (Monoclonal Antibodies, Recombinant Hormone/Proteins, Anti-Inflammatory Agents, Immunomodulators, And Others), By Manufacturing Type (In-House And Outsourced/Contract), By Application (Autoimmune Diseases, Blood Disorders, Oncology, Infectious Diseases, And Others), by geography, is projected to expand at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders such as autoimmune disorders, cancers, among others and increasing demand for biosimilar drugs owing to their cost-effectiveness.
Cancer Immunotherapy Market
https://www.delveinsight.com/report-store/cancer-immunotherapy-market
Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines, Checkpoint Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By End-User (Hospitals And Clinics, Specialty Centers, And Others), and by geography is expected to rise at a significant CAGR forecast till 2027 owing to the accelerating prevalence of cancers and surging healthcare expenditure across the globe
Companion Diagnostics Market
https://www.delveinsight.com/report-store/companion-diagnostics-market
Companion Diagnostics Market By Type (Product [Assays, Kits & Reagents And Instruments], and Services), Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Others), End-User (Hospitals, Diagnostic Labs, and Others), and Geography is expected to grow at a noteworthy CAGR till 2028 owing to the increase in the cancer burden across the globe and the growing focus on personalized medicines.
Telemedicine Service Market
https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost.
DNA Sequencing Market
https://www.delveinsight.com/report-store/dna-sequencing-market
DNA Sequencing Market By Products & Services (Instruments, Consumbales, And Services), By Technology (Sanger Sequencing, Next-Generation Sequencing, And Long-Read Sequencing), By Application (Disease Diagnosis, Precision Medicine, And Research), By End User (Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical Companies, And Academic Institutes), and by geography is estimated to grow at an appreciable CAGR forecast till 2028 owing to rising prevalence of genetic disorders and growing popularity of precision medicine.
Next Generation Sequencing Market
https://www.delveinsight.com/report-store/next-generation-sequencing-market
Next-Generation Sequencing Market By Product Type (Instruments, Reagents & Consumables And Services), By Sequencing Type (Whole-Genome Sequencing, Whole-Exome Sequencing, Rna Sequencing, Targeted Sequencing, De-Novo Sequencing, Others), By Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, Others), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Academic & Research Institute), by geography, is expected to grow at a significant CAGR forecast till 2028 owing to the rising application of next-generation sequencing (NGS) technology in clinical diagnosis and advancement in NGS platforms.
Active Pharmaceutical Ingredient Market
https://www.delveinsight.com/report-store/active-pharmaceutical-ingredient-api-market
Active Pharmaceutical Ingredient (API) Market By Type (Innovative And Generic), By Manufacturer Type (Captive And Merchant), By Synthesis Type (Synthetic And Biotech), By Application (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Opthalmology, And Others), by geography is estimated to register growth at remarkable CAGR forecast till 2027 owing to rising prevalence of various diseases such as diabetes and growing focus on drug development
Clinical Diagnostics Market
https://www.delveinsight.com/report-store/clinical-diagnostics-market
Clinical Diagnostics Market By Type (Products [Instruments, Kits & Reagents], Services), Test (Complete Blood Count (CBC), Metabolic Panel, Lipid Panel, Renal Panel, Liver Panel, Infectious Disease Testing, and Others), End-User (Hospitals, Pathology Labs, and Others), and Geography, is expected to expand at a significant CAGR till 2028 owing to the growing cases of various chronic diseases & infectious diseases across the globe and rise in the integration of technological advancements in the product portfolio.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Kidney Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Janssen Pharma, Astrazeneca, Aurobindo Pharma, Teva Pharma, Sanofi, Novartis, Sun Pharma, Bayer here
News-ID: 3311145 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
